Hospital readmission costs, dermatitis updates: Top four stories in dermatology last week

In the most popular article last week on Healio Dermatology, researchers tallied the cost of all dermatology-related hospital admissions at $27.8 billion from 2010 to 2014, while the cost of all calendar year same-cause readmissions was $2.54 billion.

In addition, PhotonMD announced clinical trial results on the efficacy of Revian Red, an all-LED cap for the treatment of androgenic alopecia, vs. a series of other hair growth devices.

Continue reading for last week’s top four stories.

 

Hospital readmission rates, costs high in dermatology

Same-day appointments for patients with flares in skin conditions, dermatology involvement at multidisciplinary clinics and the use of teledermatology for patients who are medically underserved may reduce readmissions and costs. Read more.

 

Top-line results show efficacy of LED cap for androgenetic alopecia

In the randomized, double-blind, placebo-controlled trial, Revian Red demonstrated the ability to stop hair loss and subsequently grow new hair. Read more.

 

Dupilumab significantly improves atopic dermatitis in Asian, black and white patients

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials. Read more.

 

Cell dysregulation may play role in development, exacerbation of head and neck dermatitis

The exacerbation or development of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab may be caused by a dysregulation in the balance of the T helper cell signaling pathway, according to a research letter in JAMA Dermatology. Read more.

In the most popular article last week on Healio Dermatology, researchers tallied the cost of all dermatology-related hospital admissions at $27.8 billion from 2010 to 2014, while the cost of all calendar year same-cause readmissions was $2.54 billion.

In addition, PhotonMD announced clinical trial results on the efficacy of Revian Red, an all-LED cap for the treatment of androgenic alopecia, vs. a series of other hair growth devices.

Continue reading for last week’s top four stories.

 

Hospital readmission rates, costs high in dermatology

Same-day appointments for patients with flares in skin conditions, dermatology involvement at multidisciplinary clinics and the use of teledermatology for patients who are medically underserved may reduce readmissions and costs. Read more.

 

Top-line results show efficacy of LED cap for androgenetic alopecia

In the randomized, double-blind, placebo-controlled trial, Revian Red demonstrated the ability to stop hair loss and subsequently grow new hair. Read more.

 

Dupilumab significantly improves atopic dermatitis in Asian, black and white patients

Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials. Read more.

 

Cell dysregulation may play role in development, exacerbation of head and neck dermatitis

The exacerbation or development of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab may be caused by a dysregulation in the balance of the T helper cell signaling pathway, according to a research letter in JAMA Dermatology. Read more.